Skip to content
Sherlock Biosciences logo — Improving health worldwide through accurate, fast and afford...

Sherlock Biosciences

Improving health worldwide through accurate, fast and affordable diagnostic testing

Founded 2019 United States Boston, United States 28 employees Grant Total: $137.98M Biotechnology, Health Care +1

General Information

Company Name Sherlock Biosciences
Founded Year 2019
Location United States Boston, United States
Founders / Decision Makers
Team member
Employees 28
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Sherlock Biosciences. To contact Sherlock Biosciences, visit sherlock.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Sherlock Biosciences compare?

A PDF of Sherlock Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Sherlock Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Sherlock Biosciences

Sherlock Biosciences is a biotechnology startup with a mission to revolutionize molecular diagnostics by providing accurate, fast, and affordable testing solutions. Their innovative Engineering Biology platforms are poised to address a wide array of challenges, including rapid pathogen detection, simplified cancer testing, and enhanced food safety. Their vision encompasses a world where their products empower users to make more informed decisions across various environments, from hospitals to home settings.

The company, founded in 2019, boasts a team and founders comprised of renowned experts in CRISPR, Synthetic Biology, and the diagnostic industry, alongside authorities in disease areas. This collective expertise positions Sherlock Biosciences at the forefront of transforming molecular diagnostics in both clinical and non-clinical settings.

Notably, the startup garnered significant attention with its most recent grant investment on 29 November 2022 from none other than the Bill & Melinda Gates Foundation, aligning with its aim to improve health globally. Located in the United States, Sherlock Biosciences stands as a compelling venture in the biotechnology and healthcare industries.

Business keywords: Molecular Diagnostics, Diagnostic Testing, Engineering Biology, CRISPR, Synthetic Biology, Pathogen Detection, Cancer Diagnostics, Food Safety, Health Innovation, Health Disruption, Startup, Investment Opportunity, Global Health

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
Bill & Melinda Gates Foundation
29 Nov 2022
Series B $80.00M 6
Illumina Ventures, Catalio Capital Management +4
08 Mar 2022
Venture Round $1.98M 1
Alameda Research
01 Jan 2022
Grant $7.50M 1
Open Philanthropy
21 May 2020
Series A $31.00M 3
Northpond Ventures, Baidu Venture +1
23 Apr 2019
Grant $17.50M 1
Open Philanthropy
22 Mar 2019

Sherlock Biosciences Alternatives & Competitors

View All Alternatives
Sherlock Biosciences vs
IMMY
IMMY United States

Saving Lives One Diagnostic at a Time

116 employees
Biotechnology, Health Care
Sherlock Biosciences vs

Developing cancer diagnostic panels based on epigenetic bio markers

72 employees
Biotechnology, Health Care
Sherlock Biosciences vs

Taking Point-of-Care testing to the next level.

Grant
11 employees
Biotechnology, Health Care

FAQ About Sherlock Biosciences

Improving health worldwide through accurate, fast and affordable diagnostic testing
Sherlock Biosciences was founded in 2019.
Sherlock Biosciences is headquartered in Boston, United States.
Sherlock Biosciences operates in Biotechnology, Health Care and Life Sciences. Its work centres on Molecular Diagnostics, Diagnostic Testing, Engineering Biology and CRISPR.
Sherlock Biosciences has approximately 28 employees.
Sherlock Biosciences has completed 6 funding rounds, raising a total of $137.98M. The latest funding stage is Grant.
Top alternatives and competitors to Sherlock Biosciences include IMMY, Nucleix Ltd., FRIZ Biochem GmbH, Applied BioCode, Inc., Mainz Biomed. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sherlock Biosciences and IMMY are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Sherlock Biosciences, https://bouncewatch.com/company/sherlock-biosciences, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout